同种异体CD4 T细胞维持肾移植受者BK多瘤病毒特异性CD8 T细胞应答
该前瞻性研究随访100例不同BKPyV再激活程度的肾移植受者,发现活检证实的BKPyVAN与BKPyV特异性T细胞功能耗竭及低II类HLA供受者差异相关;较高的II类HLA差异下同种异体CD4 T细胞可辅助维持BKPyV特异性CD8 T细胞应答,体外实验亦证实可挽救该应答。
要点
- 活检证实的BKPyVAN伴随BKPyV特异性T细胞增殖、细胞因子分泌和细胞毒功能丧失。
- BKPyVAN中BKPyV特异性CD4和CD8 T细胞高表达PD1等抑制性受体,呈耗竭样表型。
- 较高的II类供受者HLA差异下,同种异体CD4 T细胞可辅助维持BKPyV特异性CD8 T细胞应答。
核心结论
- 肾移植受者中同种异体CD4 T细胞可辅助维持有效的BKPyV特异性CD8 T细胞应答,更好控制移植物内BKPyV复制并可能预防BKPyVAN。
研究设计与样本
- 前瞻性随访100例肾移植受者,按BKPyV再激活程度分为无再激活、BKPyV-DNA尿症、BKPyV-DNA血症和活检证实的BKPyVAN四组,每组25例,评估BKPyV特异性T细胞功能与表型。
主要发现
- 活检证实的BKPyVAN与BKPyV特异性T细胞增殖、细胞因子分泌及细胞毒能力丧失相关。
- 该严重功能损伤伴随淋巴细胞抑制性受体PD1、CTLA-4、TIGIT和TIM-3过表达,提示BKPyV特异性CD4和CD8 T细胞呈耗竭样表型。
- 该T细胞功能障碍与低II类供受者HLA差异相关;而在较高II类供受者HLA差异背景下,同种异体CD4 T细胞可提供辅助维持BKPyV特异性CD8 T细胞应答。
- 体外实验中,同种异体HLA错配的CD4 T细胞可挽救BKPyV特异性CD8 T细胞应答。
临床怎么用
- 肾移植受者BKPyV再激活评估中可关注BKPyV特异性T细胞功能与耗竭表型。
- 供受者II类HLA差异较高时,同种异体CD4 T细胞辅助可能有助于维持BKPyV特异性CD8 T细胞应答。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: BK polyomavirus-associated nephropathy (BKPyVAN) is a significant complication in kidney transplant recipients (KTRs), associated with a higher level of plasmatic BK polyomavirus (BKPyV) replication and leading to poor graft survival. METHODS: We prospectively followed-up with 100 KTRs with various degrees of BKPyV reactivation (no BKPyV reactivation, BKPyV-DNAuria, BKPyV-DNAemia, and biopsy-proven BKPyVAN [bp-BKPyVAN], 25 patients per group) and evaluated BKPyV-specific T cell functionality and phenotype. RESULTS: We demonstrate that bp-BKPyVAN is associated with a loss of BKPyV-specific T cell proliferation, cytokine secretion, and cytotoxic capacities. This severe functional impairment is associated with an overexpression of lymphocyte inhibitory receptors (programmed cell death 1 [PD1], cytotoxic T lymphocyte-associated protein 4, T cell immunoreceptor with Ig and ITIM domains, and T cell immunoglobulin and mucin domain-containing-3), highlighting an exhausted-like phenotype of BKPyV-specific CD4 and CD8 T cells in bp-BKPyVAN. This T cell dysfunction is associated with low class II donor-recipient human leukocyte antigen (HLA) divergence. In contrast, in the context of higher class II donor-recipient HLA (D/R-HLA) divergence, allogeneic CD4 T cells can provide help that sustains BKPyV-specific CD8 T cell responses. In vitro, allogeneic HLA-mismatched CD4 T cells rescue BKPyV-specific CD8 T cell responses. CONCLUSION: Our findings suggest that in KTRs, allogeneic CD4 T cells can help to maintain an effective BKPyV-specific CD8 T cell response that better controls BKPyV replication in the kidney allograft and may protect against BKPyVAN.
引用
- Dekeyser M, de Goër de Herve MG, Hendel-Chavez H, et al. Allogeneic CD4 T Cells Sustain Effective BK Polyomavirus-Specific CD8 T Cell Response in Kidney Transplant Recipients. Kidney Int Rep. 2024. PMID: 39156165. doi:10.1016/j.ekir.2024.04.070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。